NETRI

NETRI is a pioneering organ-on-a-chip company based in Lyon, France, that has developed a proprietary, compartmentalized microelectrode array (MEA) platform in a 96-well format for high-throughput electrophysiological recording of neuronal networks. The company's core value proposition is providing pharmaceutical and dermocosmetic companies with highly predictive human-relevant data on neurotoxicity, chemotherapy-induced peripheral neuropathy, and immunogenicity, aiming to reduce clinical failures and animal testing. By combining its patented microfluidic devices with a growing Digital Signature Library of compound profiles analyzed by AI, NETRI positions itself as a key enabler for faster, cheaper, and more ethical drug development. The company operates as a B2B platform and services provider, manufacturing its devices in-house while collaborating with large pharmaceutical partners.

Proprietary 96-well compartmentalized microelectrode array (MEA) platform (NETRI UpLink®) for high-throughput electrophysiological recording of neuronal networks within microfluidic organ-on-a-chip devices. Combined with AI-driven analysis software (DataLink®) and a growing Digital Signature Library of reference compound profiles to predict neurotoxicity and adverse events.

NETRI competes in the broader organ-on-a-chip and New Approach Methodologies (NAMs) space with companies like Emulate, Mimetas, and CN Bio. Its key differentiation is its exclusive focus on neuronal networks and high-throughput, compartmentalized electrophysiology. It also faces competition from traditional in vitro neurotoxicity assays and other specialty neuroscience CROs, but its integrated platform of hardware, data, and AI is a unique combination.